Dr. Jason Alcorn covers steps 4 and 5 of the GUIDE Communication Framework, explaining how to direct the patient and carer to additional support and the importance of empowering the patient.

Watch the video and download the slides


The GUIDE Communication Framework: Strengthening shared decision-making between nmCRPC patients and the healthcare team

This is the last in a series of three newsletters explaining the GUIDE Communication Framework, a simple 5-step approach to optimise the role of the nurse in strengthening shared decision-making between nmCRPC patients and their healthcare team.

GUIDE’s five letters each represent a crucial step in your conversations with patients with prostate cancer.

  • Gain insight into goals of treatment and care
  • Understand gaps in the patient's knowledge
  • Inform and educate
  • Direct to additional support
  • Empower the patient

Dr. Jason Alcorn explains how to Direct the patient and the carer to additional support and the importance of Empowering the patient, making them feel they can actively participate in the shared decision-making and treatment process, and why these steps are an important part of a successful treatment journey.

In the first newsletter, Veerle Lamotte covered steps 1 and 2 of the GUIDE framework and explained why it’s important to Gain insight into the goals of treatment and care as a first step in supporting your patients along the agreed treatment journey and how to Understand the gaps in the patient’s knowledge, allowing you to prioritise where you focus when it comes to informing and educating the patient.

In the second newsletter, Joanie Pfahl and Jennifer Sutton covered step 3 of the GUIDE Communication Framework and explain the importance of Informing and educating the patient, and why it is essential for nurses to have up-to-date knowledge about the disease and common symptoms, key studies relating to nmCRPC, treatment aims and options, potential side effects and proactive management as addressing patients’ knowledge gaps in the right way is critical in managing their treatment successfully.

Hello, I am Dr Jason Alcorn and I'm from The Mid Yorkshire Hospitals NHS Trust in the United Kingdom.

I'm going to be talking about the strengthening shared decision-making between non-metastatic castrate-resistant prostate cancer patients and the healthcare team.

Directing the patient to additional support and Empowering the patient

This is using the GUIDE Communication Framework. I will be talking about directing to additional support and empowering the patient. If we consider the first step is directing patients to additional support, we must consider all the local options available in our areas, centres or regions.

We must consider the information provision to patients and ensuring the patient understands the information provided.

Empowering the patient by involving them in the shared decision-making process can increase the likelihood of treatment success.

As Uro-oncology nurses, we play a vital role in this process, we undertake holistic reviews of patients and ensure the patients have the right knowledge.  Factors to consider are: the physical and psycho-social aspects, such as any existing comorbidities, or barriers that the patients may face such as psychological distress of the disease.

Also understanding the treatment options of darolutamide, apalutamide and enzalutamide. These may present with potential drug interactions.  We must understand the safety profile or any polypharmacy that the patient may have and also consider bone health.

We must take into account the quality of life of the patient and also their wishes, these are paramount to involving them in their treatment and decision-making process.

To download the slides go to gunursesconnect.cor2ed.com. Thank you for listening on behalf of GU Nurses CONNECT and remember - download the slides.

Jason Alcorn is the Nurse Consultant for Uro-oncology and Andrology at the Mid Yorkshire Hospitals NHS Trust.  He has worked at the Trust for 20 years. The Mid Yorkshire Hospitals NHS Trust is a specialist cancer centre for urological cancers. Jason started in the nursing profession after a career in the military.  After completing a Bachelor’s degree developing student nurse resources, he then studied for a Master’s degree seeking to understand registered nurse understanding of delegation to healthcare assistants.  This led to him being a fellow of the higher education academy and a registered teacher.  He then studied for a professional doctorate seeking to understand why patients withdraw early from Bacillus Calmette-Guerin treatment for urothelial cancer. Jason has presented at several national and international conferences, as well as running workshops locally and in the Middle East on behalf of EAUN, and he has also published several articles from his research activity.  He is an active board member of the European Association of Urological Nurses (EAUN) and his responsibilities on the board include education, accreditation and endorsement. __________________________

Programme summary
Watch the video now
Other episodes in this series
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU NURSES CONNECT

GU NURSES CONNECT is an initiative of COR2ED, supported by Independent Medical Educational Grants from Bayer, AstraZeneca and Eisai Europe Limited.

Meet the experts

Other programmes of interest

GI-oncology-GI-CONNECT-10-years-thumbnail-GI2403 Video
Oncology 
Celebrating the 10th anniversary of GI CONNECT

10 years of independent medical education in GI oncology

Experts
Assoc. Prof. Gerald Prager, Assoc. Prof. Joleen Hubbard, Dr Thomas Winder, Prof. Andrea Sartore-Bianchi, Dr Dominik Modest
  • clock 2 MIN
  • calendar Apr 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Breast-Cancer-Connect-ER-HER2-low-thumbnail-BR2310 Tweetorial
Oncology 
Tweetorial video: Treating ER+/HER2-low metastatic breast cancer, 2L and beyond

Journey through a patient case from testing and diagnosis to treatment and AE management

Experts
Dr Aditya Bardia
Endorsed by
GRASP
  • clock 11 MIN
  • calendar Apr 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline Oncology.
NSCLC-perseverance-pays-off- thumbnail-PO2305 Podcast
Oncology 
Perseverance in molecular testing in NSCLC pays off

Looking beyond the obvious mutations in non-small-cell lung cancer

Experts
Prof. Frédérique Penault-Llorca, Prof. Mark Socinski
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer
Conference update
Oncology 
ER+ advanced breast cancer: Highlights from EBCC-14 satellite symposium

Medical experts discuss current and upcoming treatment strategies to use after CDK4/6 inhibitors in patients with ER+/HER2- advanced breast cancer

Experts
Prof. Valentina Guarneri, Prof. Matteo Lambertini, Prof. Federico Rojo
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline.
Podcast
Oncology 
mCRC: Optimising patient outcomes with late-line treatment

Maximising outcomes for patients with advanced CRC

Experts
Assoc. Prof. Gerald Prager, Dr Victor Hugo Fonseca de Jesus
Endorsed by
Digestive Cancers Europe 5th anniversary
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Interactive patient case
Oncology 
TRK fusion-positive lung cancer: Diagnosis and treatment

Make decisions for your patient at two key stages in their journey

Experts
Prof. Fernando López-Ríos, Prof. Mark Socinski
  • clock 60 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer